(NASDAQ: ANNX) Annexon's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 80.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.89%.
Annexon's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast ANNX's revenue for 2026 to be $1,065,131,037, with the lowest ANNX revenue forecast at $439,546,492, and the highest ANNX revenue forecast at $1,868,072,591. On average, 3 Wall Street analysts forecast ANNX's revenue for 2027 to be $13,605,062,794, with the lowest ANNX revenue forecast at $6,823,959,288, and the highest ANNX revenue forecast at $21,977,324,600.
In 2028, ANNX is forecast to generate $33,532,232,668 in revenue, with the lowest revenue forecast at $21,771,836,615 and the highest revenue forecast at $55,338,903,343.